H.C. Wainwright downgraded Verrica Pharmaceuticals (VRCA) to Neutral from Buy without a price target The firm cites “serious uncertainty” around Verrica’s capitalization and runway, Ycanth trajectory, and VP-315 next steps for the downgrade. It sees “real value” in Ycanth and VP-315, but is now Neutral pending further clarity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- RBC downgrades Verrica Pharmaceuticals on ‘uncertain path’ forward
- Verrica downgraded to Sector Perform from Outperform at RBC Capital
- Verrica Pharmaceuticals: Financial Struggles Amid Strategic Shifts
- Verrica Pharmaceuticals Undergoes Leadership and Financial Restructuring
- Verrica Pharmaceuticals reports Q3 EPS (43c), consensus (37c)